Anti‐androgens may protect against severe COVID‐19 outcomes: results from a prospective cohort study of 77 hospitalized men

    Andy Goren, Carlos Gustavo Wambier, Sabina Herrera, John D. McCoy, Sergio Vano-Galvan, Francesca Gioia, Belén Comeche, Raquel Ron, Sergio Serrano-Villar, Paulo Müller Ramos, Flavio A. Cadegiani, Maja Kovacevic, Antonella Tosti, Jerry Shapiro, Rodney Sinclair
    Image of study
    TLDR Anti-androgens, like finasteride, dutasteride, and spironolactone, may lessen the severity of COVID-19 in men, leading to fewer ICU admissions.
    A prospective cohort study involving 77 hospitalized men found that the use of anti-androgens could potentially reduce the severity of COVID-19 outcomes. The study divided the participants into two groups: those who had been on anti-androgens for at least 6 months before hospitalization and those who hadn't. The results indicated a significantly lower rate of ICU admission in the group taking anti-androgens (8%) compared to the group not taking them (58%), even after adjusting for age. Anti-androgens like finasteride, dutasteride, and spironolactone could potentially improve outcomes for men infected with SARS-CoV-2. However, due to the small study size, the authors recommend larger studies for further investigation.
    View this study on onlinelibrary.wiley.com →

    Cited in this study

    Related